UBS Group’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
|
|||||
|
2024
Q2 | $11.9M | Sell |
|
|||||
|
2024
Q1 | $12.9M | Buy |
|
|||||
|
2023
Q4 | $9.25M | Buy |
|
|||||
|
2023
Q3 | $2.79M | Buy |
|
|||||
|
2023
Q2 | $3.21M | Sell |
|
|||||
|
2023
Q1 | $3M | Buy |
|
|||||
|
2022
Q4 | $3.61M | Buy |
|
|||||
|
2022
Q3 | $539K | Sell |
|
|||||
|
2022
Q2 | $1.39M | Buy |
|
|||||
|
2022
Q1 | $1.29M | Sell |
|
|||||
|
2021
Q4 | $6.85M | Buy |
|
|||||
|
2021
Q3 | $243K | Buy |
|
|||||
|
2021
Q2 | $167K | Sell |
|
|||||
|
2021
Q1 | $115K | Sell |
|
|||||
|
2020
Q4 | $222K | Buy |
|